Impact of Sickle Cell Anemia on children growth and clinical parameters in Al-Ahsa region of Saudi Arabia
Abstract
Background: Sickle cell disease (SCD) is an autosomal recessive disease caused by a single gene mutation, leading to sickle-shaped red blood cells, causing many clinical complications. Resulting complications may affect the growth of the SCD patients that is a strong measure of severity of disease and helps in disease management strategies in any area. Eastern province of Saudi Arabia has one of the highest SCD incidences. Nevertheless, no studies have been previously carried out of about clinical outcome of SCD in Al-Ahsa area of eastern province. Therefore, this study was conducted to find out the impact of SCD children at king Abdulaziz Hospital Al-Ahsa.
Methods: All pediatric SCD patients were included in the study. Patient data was taken from hospital information system and analyzed using SPSS version 27.
Results: A total of 53 patients were studied. The male to female ratio was 1.4:1 and mean age was 3.3 years (range: 1-9). Eighteen (34%) did not present with sickle cell crisis possibly due to ameliorating effects of high HbF and G6PD deficiency. Although growth parameters of SCD patients were not statistically different from international standards, there was significant difference between weight of SCD patients in recurrent sickle cell crisis group and non-crisis sickle cell (NC-SC) group at diagnosis and after clinical interventions (p= 0.04 and 0.03, respectively) that included hydroxyurea. The corrected reticulocyte (at diagnosis and after clinical intervention) and WBC counts were statistically significant between hydroxyurea and non-hydroxyurea groups (p-value < 0.05).
Conclusions: Overall, one-third of SCD patients in Al-Ahsa region have mild disease and hydroxyurea can minimize the SCD severity through lowering corrected reticulocyte and WBC counts. Exact mechanisms of mild SCD and hydroxyurea in minimizing disease severity are needed to be elucidated.
Keywords: Salinity; Livelihood; Productivity; Farming experience; Farm size
Full Text:
PDFReferences
Pecker LH, Lanzkron S. Sickle Cell Disease. Annals of Internal Medicine, (2021); 174(1): ITC1-ITC16.
Piccin A, Murphy C, Eakins E, Rondinelli MB, Daves M, Vecchiato C, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. European Journal of Haematology, (2019); 102(4):319-330.
Faes C, Ilich A, Sotiaux A, Sparkenbaugh EM, Henderson MW, Buczek L, et al. Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, (2019) ;133(23):2529-2541.
Kjellander C, Sennström MK, Stiller V, Ågren A. Sicklecellanemi ger skiftande symtombild och hög morbiditet–Allvarlig prognos vid världens vanligaste genetiska sjukdom [Sickle cell anemia causes varied symptoms and high morbidity. Serious prognosis in the most common genetic disease in the world]. Lakartidningen. (2015);112:DCPM.
Williams TN, Thein SL. Sickle Cell Anemia and Its Phenotypes. Annual Review of Genomics and Human Genetics, (2018); 19: 113-147.
Kapoor S, Little JA, Pecker LH. Advances in the Treatment of Sickle Cell Disease. Mayo Clinic Proceedings (2018); 93(12): 1810-1824.
WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatrica, (2006);450:76-85.
Jastaniah W. Epidemiology of sickle cell disease in Saudi Arabia. Annals of Saudi Medicine, (2011);31(3):289-93.
Mitchell MJ, Carpenter GJ, Crosby LE, Bishop CT, Hines J, Noll J. Growth status in children and adolescents with sickle cell disease. Pediatric Hematology Oncology, (2009); 26(4): 202-15.
Adesina OO, Gurney JG, Kang G, Villavicencio M, Hodges JR, Chemaitilly W, et al. Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. Blood Advances, (2019) 14; 3(9): 1476-1488.
Adegoke SA, Figueiredo MS, Adekile AD, Braga JAP. Comparative study of the growth and nutritional status of Brazilian and Nigerian school-aged children with sickle cell disease. International Health, (2017); 9(6): 327-334.
Al-Suliman A, Elsarraf NA, Baqishi M, Homrany H, Bousbiah J, Farouk E. Patterns of mortality in adult sickle cell disease in the Al-Hasa region of Saudi Arabia. Annals of Saudi Medicine, (2006); 26(6):487-8.
Sales RR, Belisário AR, Faria G, Mendes F, Luizon MR, Viana MB. Functional polymorphisms of BCL11A and HBS1L-MYB genes affect both fetal hemoglobin level and clinical outcomes in a cohort of children with sickle cell anemia. Annals of Hematology, (2020); 99(7):1453-1463.
Belisário AR, Sales RR, Toledo NE, Velloso-Rodrigues C, Silva CM, Viana MB. Glucose-6-Phosphate Dehydrogenase Deficiency in Brazilian Children With Sickle Cell Anemia is not Associated With Clinical Ischemic Stroke or High-Risk Transcranial Doppler. Pediatric Blood & Cancer, (2016);63(6):1046-1049.
Esrick EB, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, et al. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. The New England Journal of Medicine, (2021); 384(3): 205-215.
Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: Prevalence and resource utilization. PLoS One, (2019); 14(7): e0214355.
Hankins JS, Aygun B, Nottage K, Thornburg C, Smeltzer MP, Ware RE, et al. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia. Medicine (Baltimore), (2014); 93(28): e215.
Rana S, Houston PE, Wang WC, Iyer RV, Goldsmith J, Casella JF, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics, (2014); 134(3): 465-72.
Pule GD, Mowla S, Novitzky N, Wiysonge CS, Wonkam A. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease. Expert Review of Hematology, 2015; 8(5): 669-79.
DOI: http://dx.doi.org/10.62940/als.v8i2.1119
Refbacks
- There are currently no refbacks.